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1. Introduction 
The antisynthetase syndrome (ASS) was first described by Marguerie and coworkers in 1990 
as a triad of polymyositis, diffuse interstitial lung disease (ILD) and serum autoantibodies to 
aminoacyl transfer RNA synthetases (anti-ARS) (1). Later, cohort studies have indicated that 
20-25 % of patients diagnosed with polymyositis (PM) or dermatomyositis (DM) have anti-
ARS antibodies (2-4). In most cases, these anti-ARS+ PM/DM patients also have ILD. The 
ILD is, in fact, the major determinant of morbidity and mortality in the ASS.  
The most common of the anti-ARS, anti-Jo-1, was first described in 1980. Three years later, 
the Jo-1 antigen was identified as histidyl-tRNA synthetase (5;6). In recent case series, the 
anti-Jo-1 antibody accounts for 68-87% of the anti-ARS observed in ASS (7-9). The seven 
other anti-ARS identified (Table 1) are all rare, but their relative frequencies have not been 
extensively studied (7;8). With very few exceptions, each patient has only one anti-ARS 
antibody (10). More than half of the anti-ARS+ patients also possess anti-SSA autoantibodies 
(8;9;11) and then most frequently anti-Ro52 (11). 
2. Disease definition  
At present, there is no internationally accepted definition of ASS and no classification 
criteria have been established. Consequently, the clinical characteristics of published ASS 
cases vary substantially. Some studies have included all patients with anti-ARS, regardless 
of clinical manifestations, while others have selected patients according to predefined 
clinical features.  
As it is generally agreed upon that ILD is the clinical hallmark of ASS, this clinical feature is 
regarded mandatory for the diagnosis of ASS by most workers. The finding of ILD in 64-100 
% of patients possessing anti-Jo-1 autoantibodies underlines the close association between 
anti-ARS and ILD (3;9;12-17). In one study (3), anti-ARS were found in 3% of DM without 
ILD as opposed to 63% in DM with ILD, further emphazising the importance of pulmonary 
disease in ASS. Thus, ILD is an important but not a compulsory feature of ASS diagnosis. 
In ASS, the extent and severity of myopathy may vary considerably (18). Usually, the 
myositis is less severe than in DM and PM without anti-ARS. Some cases develop clinically 
overt myositis, others present with hypomyopathic or even amyopathic disease. Thus, a 
diagnosis of ASS should be considered even in the absence of myositis.  
Criteria for the ASS have been proposed recently (19). These criteria suggest that a diagnosis 
of ASS could be made in the presence of positive serologic testing for an anti-ARS plus one 
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of the following; myositis, ILD, arthritis, fever, Raynaud`s phenomenon or Mechanic`s 
hands. We feel, however, that ILD and myositis represent the most important clinical 
features of ASS, hence at least one of them should be included in such classification criteria. 
It is thus tentatively suggested that a diagnosis of definite ASS should require anti-ARS and 
either ILD and/or inflammatory myopathy plus at least one other clinical criterion 
commonly found in this syndrome (Table 2). A diagnosis of probable ASS would be met 
when either ILD and/or inflammatory is present in a patient with anti-ARS.  
3. Epidemiology  
ASS is a rare disease, but its frequency in the general population is not known. In most 
studies, the estimated population prevalence of PM/DM is around 15/100 000 (refs). If 25% 
of the PM/DM patients have anti-ARS, then the prevalence of the anti-ARS should be least 
3-4/100 000. ASS has been reported in both Caucasian, Asian and Afro-American patients, 
but it is known if the prevalence of the disease differs between ethnic groups.  
The age at onset among adults ranges from 19 to 82 years with a mean age at onset varying 
from 43 to 60 yrs (2;3;9;12;20). Very few children and adolescents with ASS have been 
reported. A female dominance, with about twice as many females as men affected, has been 
found in most series (3;9;12).  
4. Pathology 
Muscle. The results of histological examination of muscle tissue are somewhat conflicting. 
In one early study (21), the authors demonstrated prominent perimysial inflammation with 
fragmentation and perifascicular myopathic changes whereas endomysial inflammation was 
uncommon. Consequently, these findings suggested a dermatomyositis pattern in ASS 
rather than polymyositis. In subsequent reports, the picture has become less clear as a 
polymyositis pattern has been more commonly observed than a dermatomyositis pattern 
(13;22). Some studies have, however, concluded with similar frequencies of polymyositis 
and dermatomyositis in ASS (8;23). In our own experience, the majority of cases exhibit 
changes compatible with a diagnosis of dermatomyositis. The frequent occurrence of 
dermatological lesions to some extent supports a closer relationship to dermatomyositis 
than to polymyositis. Moreover, the frequent findings of vasculopathic changes at nail fold 
capillaroscopy may also favor a vasculopathic genesis rather than a myopathic one. Further 
studies of muscle and vessel pathology in ASS are clearly warranted. 
Lung. Limited pathologic case series have shown that the ILD in ASS encompasses various 
histologic subtypes and both non-specific interstitial pneumonia (NSIP), usual interstitial 
pneumonia (UIP), cryptogenic organizing pneumonia (COP) and diffuse alveolar damage 
(DAD) may be diagnosed (20;24;25). 
5. Genetics 
Most works on the genetics of ASS have been confined to candidate genes in the very 
polymorphic Human Leukocyte Antigen (HLA) region. All the published studies confirm 
that the HLA-DRB1*0301, DQA1*0501 and DQB1*0201genes are risk factors for the 
development of anti-Jo-1+ ASS (7).  
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6. Disease mechanisms 
Already in the 1980’s it was speculated that the in vivo formation of anti-histidyl tRNA 
synthetase antibodies was driven by viral infections, possibly through molecular mimicry 
between viral proteins and histidyl tRNA synthetase (HRS) (26). The basic idea was that the 
cross-reactive anti-HRS (anti-Jo-1) caused damage through its ability to inhibit HRS and/or 
through formation of immune complexes . Although never backed by experimental 
evidence, the viral hypothesis is still highlighted in many reviews on ASS.  
More recent studies have focused more on auto-antigenic properties of the HRS molecule 
per se. A very interesting finding in this respect, was that soluble HRS acted as a chemokine 
and attracted CD4+ T cells (27). In inflamed tissues marked by cell destruction and high 
concentrations of free HRS this mechanism could contribute to the breaking of tolerance 
(27). Another observation has been that HRS expression is upregulated in regenerating 
muscle cells. Areas with active myositis should thus have very high expression of HRS. 
Together, these studies indicate that muscle inflammation per se may increase the levels of 
HRS and the likelihood of initiating immune responses to HRS, at least in genetically 
susceptible individuals. Whether similar mechanisms are operative in the lung is not 
known, but it has been suggested that HRS adopts a more immunogenic conformation in 
the lung than in blood cells (28). Previously, it was shown that T cells from the blood of both 
ASS patients and healthy individuals often recognized HRS (29). No data on T cell or B cell 
reactivities to HRS in inflamed muscle or lung exist, but CD4+ T cells from the 
bronchoalveolar lavage fluid of two anti-Jo-1+ ASS patients have been shown to contain the 
same T cell receptor gene family (30). 
7. Clinical features 
Disease onset. At onset of disease, respiratory symptoms are present in 40-60 % of patients. 
In one case series (3), the onset of ILD preceded the onset of myositis in 33%, while myositis 
and ILD developed simultaneously in 60%. Myositis preceding ILD was observed in only 
7% of the patients. At onset of disease, patients may also present with constitutional 
symptoms such as fever (seen in 35-90% of the patients), loss of appetite and weight loss 
(2;3;31;32). Other features seen at onset of ASS are joint pain, arthritis, tenosynovitis, and 
Raynaud`s phenomenon.  
Respiratory symptoms. The reported frequency of ILD in ASS varies, depending on patient 
selection and the sensitivity of the tests applied to detect ILD (18). Most reports indicate that 
the frequency of ILD in the ASS is in the range of 70-95 % (3;9;12-14;16;31), but some few 
case series have found lower frequencies (2;33). The frequency of ILD appears to be highest 
among ASS patients who are anti-PL12 positive, as ILD was diagnosed in 90-100% of PL-12 
positives as compared to 50-75% in Jo-1 positives (20;34). 
Most frequently, patients complain of shortness of breath and cough. The lung disease may 
present very acute, subacute or asymptomatic ILD with development of clinically apparent 
ILD later on. Consequently, the type of onset may be classified into three groups, type I 
acute, type II gradual and type III asymptomatic. Such a classification may be important for 
predicting outcome and selecting optimal treatment.  
Muscle weakness is reported at onset of disease in 20-50 % of patients. Most commonly, it 
involves the proximal and axial muscles (31;33). Patients may also report muscular stiffness 
and pain. The muscular component is thus indistinguishable from that seen in PM and DM. 
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However, muscle involvement is less frequent and usually milder than in non-ASS patients 
(18). The reported accumulated incidence of myositis ranges from 40-94% (3).  
The tendency to milder myositis among cases with PL-12 was further supported by the 
findings of a frequency of 60% PL-12 among patients without clinically evident myositis 
(35). ASS may also present with a hypo- or even amyopathic dermatomyositis pattern. 
Skin symptoms. Dermatological features are frequently encountered in ASS, being 
observed in 7-70% of the various reports (3;9;12;14;32;33). Mechanic`s hands appear as 
fissuring and scaling of the lateral and distal aspects of the hand, and is rarely seen in 
conditions other than ASS. In ASS, this clinical feature is seen in 0-32% of cases (3;9;12;31-
33). Histological examinations of biopsy specimens of Mechanic`s hands have displayed 
mononuclear cell infiltrates around the blood vessels and mucin deposition in the dermis 
(36). As in DM, heliotrophic rash is seen in 7-38% (3;14;31;36). Gottron`s lesions appearing 
on bony prominences such as finger knockles are observed in 9-69% of patients (3;31;33;36). 
Microvascular changes presenting as periungual erythema may also be seen (1). Although 
infrequently reported, V-sign and Shawl-sign may also develop in ASS. 
Joint pain or swelling. Arthritis is a frequent clinical manifestation of ASS, being seen in 42-
82% of reported cases (2;3;9;12;14;36). Although rare, a subluxating arthropathy involving 
the distal joints of the fingers (37) is a rather characteristic feature of ASS. ASS may also 
present as a symmetric inflammatory polyarthritis initially indistinguishable from that of 
rheumatoid arthritis (38). Tenosynovitis has also been reported. Joint pain without signs of 
inflammation also occur frequently in ASS (66-89%) (2;32). 
Gastrointestinal symptoms. Involvement of the gastrointestinal canal is usually restricted to 
the distal parts of the oesophagus. The incidence of distal oesophageal dysmotility evidently 
depends on the tests used to identify the abnormality, but is diagnosed in 5-52% of the 
reports (9;12;31-33). Oesophageal disease is an important clinical feature of ASS as 
dysphagia leading to aspiration may further damage the already compromised pulmonal 
function. In patients with end stage interstitial lung disease, this manifestation may restrict 
patients`possibilitis of being accepted for lung transplantation. Routine examinations using 
barium enema x-ray is therefore recommended to diagnose oesophageal dysmotility which 
should be treated vigorously. 
Vascular symptoms. Clinical signs of vasculopathy may appear. Raynaud`s phenomenon 
accompanies ASS in 30-50 % of cases (2;3;9;12;14;20;32). Skin necrosis and ischemic ulcera 
have also been observed in ASS (39). Pulmonary arterial hypertension has not been 
subjected to studies aimed at detecting its true incidence that is using echocardiography to 
screen all cases. It is, however, infrequently observed in DM and PM, and in one study (43) 
PAH was diagnosed by echocardiography in 16 of 198 consecutive cases (0,8%). It was thus 
concluded that mild to severe PAH is a rare complication of IIM (43). In ASS, cases with 
fatal (40) and acute (41-43) PAH have been observed. In our patient cohort of 67 cases of 
ASS, PAH diagnosed by right heart catherization was observed in nine cases and 
represented a frequent cause of death in this syndrome.  
Other clinical features seen rather commonly in ASS include, sicca symptoms (8-54%) 
(2;9;31;32), sclerodactyli (12) and subcutaneous calcinosis (44). Glomerulonephritis may be 
seen (45).  
Clinical features stratified by anti-aaRS. In general, the similarities of the clinical features 
among patients possessing different ASS are rather impressive. Some differences have, 
however, been suggested. Due to low numbers of non-Jo-1 positive ASS patients reported, it 
is prudent that these differences are considered preliminary and interpreted cautiously. 
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Among PL-12 positive ASS, the histological features of ILD is predominantly of the NSIP 
pattern (20), while myositis is mostly mild (34). In one study (20), CK levels increased to up 
to twice the normal level in only two individuals. Interestingly, two of these cases were 
diagnosed with PAH.  
Patients with anti-PL7 autoantibodies may also show different clinical features when 
compared to Jo-1 positives. Anti-PL-7 autoantibodies have been associated with milder 
muscle weakness (46) and almost all patients reported have had ILD (46;47). Seven patients 
with anti-OJ autoantibodies were described by Sato et al (48) of whom all had ILD, and four 
presented muscle weakness and polyarthritis. None had Raynaud`s phenomenon or 
sclerodactyli. In a study of eight patients with anti-KS autoantibodies, 88% had ILD 25% 
(49). 
Other clinical associations. Anti-SSA antibodies, anti-Ro52 in particular, occur in more than 
50% of ASS (8;11) and have been associated with more severe lung fibrosis (13). In one study 
(50) patients without anti SSA autoantibodies more often lacked fibrosis on the initial CT 
scans compared to patients possessing these autoantibodies. In another study (33), patients 
with such autoantibodies seemed to be predisposed to the development of a more severe 
ILD as assessed by both HRCT and lung function tests. 
8. Disease associations 
Cancer. The increased risk of cancer in DM is well documented. In one study of 103 patients 
with DM, 15 patients had concomitant malignancy (51) and the risk of cancer was highest 
among those without myositis-specific autoantibodies. Thus, ASS was suspected to provide 
some protection against the development of cancer. However, subsequent case reports of 
concurrent ASS and cancer appeared (52;53), clearly showing that ASS does not provide 
total protection against development of malignant disease. Whether or not the risk of cancer 
is less in ASS compared to other IIM remains to be studied. However, in a recent study from 
Japan , 4.8 % of patients with DM and concomitant cancer possessed anti-Jo-1 antibody as 
opposed to 15.9 % in DM patients without malignant disease (54). Although these findings 
may indicate some protective effect of anti-ARS against development of malignancy, further 
studies are warranted to corroborate such an association. 
Other immune-mediated disorders. Approximately 5-8 % of anti-ARS cases manifest as 
overlap syndromes with another connective tissue disease such as systemic lupus 
erythematosus, systemic sclerosis and Sjøgren`s syndrome (55).  
9. Evaluation and diagnosis 
Assessment of the respiratory system. The diagnosis of ASS associated ILD is based on 
HRCT of lungs. Ground glass opacities, subpleural fibrosis and bronchiectasies, all due to 
compromise of the alveolar-capillary interface, may be observed early in the disease course. 
In some cases, the progression of ILD is severe, culminating in end stage pulmonal disease 
(honeycombing) after a rather short disease duration. In other cases, more limited 
abnormalities on HRCT are seen with little impact on lung function.  
 Lung function tests typically reveals a restrictive pattern with FVC or total lung capacity 
less than 80% of the predicted value for age and height and a decrease in the diffusing 
capacity for carbon monoxide. As lung function tests are readily reproducible and 
minimally invasive, such tests are recommended both for uncovering occult ILD and for 
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monitoring disease severity and disease progression. Lung biopsy offers unclear prognostic 
value (19), and is not recommended as a routine procedure in the evaluation of ASS.  
Assessment of the musculoskeletal system. Evaluation of muscular involvement reveals in 
the majority of cases significant elevations of creatin kinase (CK). Compared to PM, the 
elevations of CK are often modest, in the majority of cases not exceeding 5000 IU/ml (2;3;9). 
In a few cases, however, the myositis is severe, exhibiting CK levels of several thousands 
and causing severe muscular weakness. MRI will in cases of clinically overt disease show 
oedema initially, and by time development of fibrosis, fatty deposits and atrophy. In 
hypomyopathic patients, MRI and CK levels may be normal in spite of muscular weakness. 
In other cases of hypomyopathic ASS, there are no muscle complaints while CK levels may 
be elevated or MRI may show signs of inflammation. Amyopathic ASS denotes a condition 
in which neither clinical symptoms nor laboratory abnormalities are present.  
10. Assessment of other organ systems 
Further evaluation of patients with ASS should include barium oesophageal x-ray which in 
more than 25 % of cases will reveal distal oesophageal dysmotility. Diagnosis and proper 
treatment of oesophageal dysmotility is important to avoid further damage to the lungs by 
aspiration. Another important disease complication is represented by pulmonary 
hypertension, either pre- or post capillary. Echocardiography should therefore be 
considered in the work-up of ASS. If PAH is suggested by echocardiography, the diagnosis 
should be verified by right heart catherization. Capillaroscopy may show reduced capillary 
density (56), and in two studies nailfold capillary changes were detected in 31 and 89%, 
respectively (3;9). Whether or not the occurrence of such vasculopathic changes differ 
between those with a histologic pattern of dematomyositis as oppsoded to polymyositis 
remains to be studied. 
11. Evaluation of disease activity and disease severity 
Biomarkers for disease activity and disease severity have been incompletely studied in ASS. 
Whether or not traditional markers for acute phase responses such as SR and CRP correlate 
with the actual activity and progression of disease remains to be seen. In the initial phases of 
disease, an acute phase response may be evident. One study suggested that levels of  
anti-Jo-1 autoantibodies correlated with disease activity (12), but these findings await 
confirmation. Thus, further research of ASS biomarkers for disease activity and disease 
severity should be strongly encouraged. 
12. Treatment 
Treatment of ASS is a challenge as no controlled trials have been performed and 
recommendations are based on single case reports and small patient series.  
 Standard treatment regimes include corticosteroids in addition to immunosuppressives. 
The role of corticosteroids in ASS associated ILD and their potential impact on disease 
course and patient survival is, however, unclear. Corticosteroids have little prospective 
evidence supporting their use (19), but their well documented intense anti-inflammatory 
efficacy suggests that they may be an essential part of initial therapeutic regimen. Moreover, 
the efficacy of corticosteroids in suppressing myositis is well documented. Thus, most 
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clinicians regard corticosteroids as a basic part of the therapeutic regimen of ASS. In acute or 
subacute pulmonary disease, high doses of oral glucocorticosteroids are usually 
administered (1 mg/kg/day). At some centers, intravenous methylprednisolon in doses of 
500-1000 mg/day for 2-3 consecutive days are used as initial treatment. It should be noted, 
however, that there are no studies that clearly show the superiority of intravenous to oral 
corticosteroid treatment. In gradually developing ILD (type II) moderate doses of 
corticosteroids (0.5 mg/day initially) are most often preferred. 
There is unfortunately no general consensus to what immunosuppressives that should be 
preferred in addition to corticosteroids in ASS. Although placebo-controlled trials are 
lacking, favorable experiences with cyclophosphamide in other connective tissue diseases 
have led many clinicians to prefer this drug as an adjunct to steroids. The choice of 
immunosuppressive treatment, however, clearly depends on the severity and extent of 
disease. In moderate to mild cases, a combination of oral glucocorticosteroids and either 
cyclophosphamide, azathioprine or methotrexate may be recommended. However, in our 
experience this regimen is insufficient in cases with acute and rapidly progressing ILD. 
Although based on retrospective case series, we recommend a combination of oral 
corticosteroids, cyclophosphamide and the anti-CD-20 monoclonal antibody rituximab as 
induction therapy in type I ASS (57). The efficacy of rituximab has also been reported in 
several case reports (58;59).  
Others have experienced favorable effect of calcineurin inhibitors such as cyclosporin A (60) 
and tacrolimus (23). Another therapeutic option is mycophenolate mofetil and for myositis 
methotrexate may be valuable as an adjunct to corticosteroids. Clearly, multicenter 
randomised controlled studies of the efficacy of immunosuppressive therapy in ASS is 
highly warranted. 
In end stage pulmonary disease, lung transplantation appears the only therapeutic option, 
but is rarely accepted due to oesophageal dysmotility. The dermatological manifestations 
may be favorable treated by hydroxychloroquine. 
13. Disease outcome 
The final outcome of ASS largely depends on the type and progression of ILD. Myositis 
have usually limited impact on outcome. The majority of patients run a chronic disease 
course (24) and will require immunosuppressive therapy for several years. Unfortunately, 
no follow-up study including a large number of patients have been performed to display the 
impact of ASS on functional outcome and quality of life. In one study of 12 patients followed 
for 5.5 years, muscle function improved in all and pulmonary function normalized in 1/3 
(32). 
In a study of 32 patients (61), patients with acute onset and respiratory insufficiency were 
compared to those with a gradual onset of ILD. The percentage of patients in whom the ILD 
improved at three months was significantly higher among those with acute onset. However, 
most patients with ILD progression after 12 months were among those with acute onset. 
Other studies have also shown an association between acute and subacute onset and poor 
prognosis (62). 
Whether or not the pattern of HRCT findings is indicative of final outcome is a matter of 
debate. Ground glass opacities, initially thought to represent reversible inflammation have 
been associated with a better response to therapy (63), hence a more favorable outcome. 
However, ground glass opacities may also represent fine reticular fibrosis, and some studies 
have suggested a poor prognosis in patients demonstrating such changes (64). Finally, 
mortality appears to have little relationship to biopsy subtype (19). 
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Mortality and causes of death in ASS have been rarely subjected to investigation. After an 
average of 5.5 years, only one of 12 patients succumed ((32) and mortality was estimated to 
8%. Others have found a cumulative mortality of 14% (9). At present, the overal annual 
mortality of ASS cannot be exactly assessed, but it can be concluded that ASS is associated 
with excess mortality. 
In general, the mortality in IIM has improved during the last decades, from a 5-year survival 
of 65% in the 1960ies compared to 75-96% in the last decade (65). If modern therapy and 
more aggressive therapy have had the same impact on ASS remains to be seen. 
14. Future perspectives  
ASS represent a rather newly defined disease entity whose etiopathogenesis remains 
incompletely understood. The disease course is usually chronic and ASS is most likely 
associated with decreased survival. Due to its low incidence large scale prospective 
investigations are few. Knowledge about the clinical aspects of ASS has accumulated, while 
outcome, prognostic markers, biomarkers for disease activity, treatment, mortality and risk 










Table 1. Antisynthetase autoantibodies. 
 
Antisynthetase autoantibody 
demonstrated on two separate occasions 
Plus at least one of the following 
Plus Arthritis/arthralgia 
Either Interstitial lung disease Raynaud`s phenomenon 
And/or Inflammatory muscle disease Gottron`s paples or sign 
 Mechanic`s hands 
 D 
Table 2. Suggested classification criteria for ASS. 
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